Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (...
Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research
NASHVILLE, Tenn., July 6 /PRNewswire/ -- A Pebble Beach golf tournament pays off big for researchers looking for a cure for multiple
sclerosis. The researchers took home the top prize: a $150,000 contribution from multi-platinum recording artist Clay Walker and the non-profit Band Against MS (BA...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
- Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma
- Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of non-Hodgkin's lymphoma
EAST HANOVER, N.J....
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple
Myeloma Patients - Proteolix Expands Trial
ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most ...
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) A...
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials -
- Company to Hold Investor Event on Sunday, May 31 with Oncology Experts -
SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today ann...
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
- Primary Endpoint met With a Significant Reduction in Relapse Rate
- Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression
- Submission for Registration of Cladribine Tablets Planned for mid-2009
SEATTLE and GENEVA, April 30 ...
New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins--commonly prescribed to lower cholesterol--may benefit men with prostate cancer, erectile dysfunction or ...
Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
- Data Presented at the American Association for Cancer Research -
PRINCETON, N.J., April 21 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced preclinical efficacy and safety data from multiple
programs, including antibodies to novel and potentially important cancer ta...
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System -
- Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic C...
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources
WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceut...
XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals
Ltd. (Nasdaq: XTLB ; TASE: XTL) announced today that it has entered into an
asset purchase agreement with Bio-GAL Ltd, a private company, for the rights
to a use patent on Recombinant Erythropoietin ("rHuEPO") for the...
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression
NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...
Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple
sclerosis. ARX424 was created by A...
Young Smokers Increase Risk for Multiple Sclerosis
SEATTLE, Feb. 23 /PRNewswire-USNewswire/ -- People who start smoking before age 17 may increase their risk for developing multiple
sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May...
New Study Proves Multiple Births From IVF Can Be Avoided
Recent Research by Shady Grove Fertility Center Proves that elective Single Embryo Transfer is Effective in Reducing Multiple
ROCKVILLE, Md., Feb. 3 /PRNewswire-USNewswire/ -- As fertility experts across the nation bemoan the health risk and expense of multiple
births such as the octu...
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
Program Expands on Successful Results from prior U.S., U.K. and China Trials
SAN DIEGO, Jan. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, today announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 cli...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported updated results from two large, multi-center,
randomized Phase III clinical trials of VELCADE based combinations for the
induction treatment of transplant-eligible patients with previously untreated
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported the Phase I results from a randomized, multi-center,
Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide
and lenalidomide (VcDCR) in patients with previously untreated multiple
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Presentations Will Highlight Research Conducted in GenVec Malaria Vaccine Program
GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) announced today that the company will present on GenVec's malaria vaccine program at the American Societ...
Aiming at Multiple Alzheimer's Proteins May be Key to Success
CLARKSBURG, Md., Oct. 21 /PRNewswire/ -- An independent team of
scientists is leading Alzheimer's disease research in a new, promising
direction. Through a $1 million grant they received last year from
Alzheimer's Disease Research, a program of the American Health Assistance
Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
CLARKSVILLE, Md., Oct. 13 /PRNewswire/ -- Neuronascent, Inc.
( http://www.neuronascent.com ) announced today that the Company has received
funding from multiple
sources to further the development of its novel,
neurogenic compounds targeting Alzheimer's disease, depression and
Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty
Pharmacy announced today that Teva Neuroscience has selected Diplomat
Specialty Pharmacy to be one of only three sites to participate in a large
scale, national Therapy Optimization Study for Multiple
Sclerosis (TOP MS).
Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
Design Concept of Other Product - Company's Bioabsorbable Stent - Also
Slated for Presentation at Symposium
HONG KONG, Oct. 6 /PRNewswire/ -- Data from multiple
clinical trials of
the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R
stent, will be presented next week at t...
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
- Conference call webcast Monday, 5:00 p.m. EDT and Tuesday, 7:00 a.m.
Australian EST at http://www.antisense.com.au and http://www.isispharm.com
MELBOURNE, Australia and CARLSBAD, Calif., Sept. 22
/PRNewswire-FirstCall/ -- Antisense Therapeutics Ltd. (ASX: ANP) and Isis
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
- ORACLE MS Phase III Trial Will Assess Effectiveness of Cladribine Tablets
in Preventing Conversion to Definite Multiple
Sclerosis in Addition to the Fully Enrolled Phase III Pivotal Trial - - the CLARITY Study - - for Treatment of Relapsing Forms of...
Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
GENEVA, Sept. 17 /PRNewswire/ -- Merck Serono, a division of Merck
KGaA, Darmstadt, Germany, announced today that patient enrollment has been
completed in the REFLEX trial (Rebif FLEXible dosing in early multiple
sclerosis). This randomized, double-blind, placebo-controlled,
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers -
ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from
an ongoing randomiz...
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
- Patients in the VELCADE, melphalan and prednisone arm demonstrated a
significant survival benefit as well as a 30 percent complete response -
CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda
Oncology Company today announced the publication of results from the 682
SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
INDIANAPOLIS, Aug. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc.
announced data presented at the Seventh International Congress on Targeted
Therapies in Cancer in Washington, D.C., showing additional antiangiogenic
activity of vascular-targeted PI3 kinase (PI3K) inhibitor SF1126, by
First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
Identifies deadly hospital pathogens A single, fast and accurate test identifies four Staph strains simultaneously
HUNTSVILLE, Ala., Aug. 4 /PRNewswire/ -- Diatherix Laboratories, an
independent clinical reference laboratory located in the Huds...
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately
held biotechnology company, announced today the grant of US Patent Number
7,381,790 (the '790 patent) which protects the composition of matter for
its PI-2301 peptide copolymer for the treatment of autoimmune diseases.
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Provides Update on Carfilzomib Development Program in Multiple
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
today announced that patient dosing has commenced in a Phase 1b clinical
trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately
held biotechnology company, announced that physicians have treated the
first participant in a clinical trial to evaluate the safety, tolerability,
pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
WAYNE, N.J. and EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ --
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
(Nasdaq: ONXX ) today announced the presentation of new clinical data from
the early clinical trials in the development program for Nexavar(R)
Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
- Poster Presented at ASCO Annual Meeting -
SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/
-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical
company focused on oncology, today announced safety and efficacy results
from a previously unp...
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of results from three
clinical trials of VELCADE based therapies that showed consistently high
complete remission(1) (CR) rates in patients with newly diagnosed multiple
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
-- IFM presents updated results from Phase III clinical trial --
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of updated results from
a 482 patient, multi-center, randomized Phase III clinical trial, comparing
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
BERKELEY HEIGHTS, N.J., May 21 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced that multiple
featuring its lead oncology products will be featured at the 44th annual
meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May
30 - Jun...